Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906181 | 0.82 | DPP4 (0.49) | GAAHTTCYP2C9DPP7USP2 | |
| SCHEMBL28985321 | 0.68 | HTT (0.58) | GAAHTTCYP2C9HPGDUSP2 | |
| SCHEMBL24858699 | 0.67 | ALDH1A1 (0.43) | HTTCYP2C9TSHRLMNAKMT2A | |
| SCHEMBL1590241 | 0.66 | TSHR (0.59) | GAAHTTCYP2C9HPGDTSHR | |
| SCHEMBL15617312 | 0.66 | TSHR (0.59) | GAAHTTCYP2C9HPGDTSHR | |
| SCHEMBL6474890 | 0.65 | GAA (0.96) | GAAHTTCYP2C9HPGDUSP2 | |
| SCHEMBL26180022 | 0.65 | HPGD (0.50) | GAAHPGDTSHRLMNAEPHX2 | |
| SCHEMBL28731719 | 0.65 | ALDH1A1 (0.47) | GAAHTTCYP2C9HPGDTSHR | |
| SCHEMBL28795080 | 0.65 | NR1H2 (0.51) | HTTDPP7HPGDTSHRLMNA | |
| SCHEMBL15114732 | 0.65 | NR1H2 (0.51) | HTTDPP7HPGDTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198445-B2 | Phosphoramide compound, method for producing the same, ligand, complex, catalyst and method for producing optically active alcohol | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100113786-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113786-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1C, ADH1A, DERA | GAA 2907/4885HTT 4744/4885CYP2C9 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.